EDSA Key Statistics, Chart & Performance
The current stock price of EDSA is 1.5 USD. In the past month the price decreased by -14.77%. In the past year, price decreased by -15.49%.
EDSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About EDSA
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Company Info
EDESA BIOTECH INC
100 Spy Crt
Markham ONTARIO L3R 5H6 CA
CEO: Pardeep Nijhawan
Employees: 16
Phone: 19054751234
EDESA BIOTECH INC / EDSA FAQ
What does EDSA do?
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Can you provide the latest stock price for EDESA BIOTECH INC?
The current stock price of EDSA is 1.5 USD. The price decreased by -0.66% in the last trading session.
Does EDSA stock pay dividends?
EDSA does not pay a dividend.
How is the ChartMill rating for EDESA BIOTECH INC?
EDSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy EDSA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EDSA.
What is the employee count for EDSA stock?
EDESA BIOTECH INC (EDSA) currently has 16 employees.
Can you provide the market cap for EDESA BIOTECH INC?
EDESA BIOTECH INC (EDSA) has a market capitalization of 10.56M USD. This makes EDSA a Nano Cap stock.
EDSA Technical Analysis
EDSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EDSA. While EDSA has a great health rating, there are worries on its profitability.
EDSA Financial Highlights
Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.35. The EPS increased by 30.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.11% | ||
| ROE | -57.71% | ||
| Debt/Equity | 0 |
EDSA Forecast & Estimates
8 analysts have analysed EDSA and the average price target is 11.22 USD. This implies a price increase of 648% is expected in the next year compared to the current price of 1.5.